Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Status:
RECRUITING
Trial end date:
2031-11-01
Target enrollment:
Participant gender:
Summary
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Phase:
PHASE2
Details
Lead Sponsor:
Children's Hospital of Philadelphia
Collaborators:
Eli Lilly and Company United States Department of Defense